BreathDx.ai is a United States and Malaysian based medical diagnostics company which has collaborated in the development of BREATHGUARD, the first micro gas chromatography based test to noninvasively detect various illnesses using exhaled breath to locate identified volatile organic compounds.
Our mission is to save lives through early noninvasive cancer detection and to become the world’s leading breath-based diagnostics company. Our lung cancer test is scheduled to launch commercially Q2 2024. We will initially operate through CLIA Labs, urgent care centers, and therapeutic infusion centers in the United States.
The global cancer diagnostics market size was valued at $138 billion in 2022 and is expected to generate $279 billion by 2032 with a CAGR of 7.4%.
Our clinical trial collaborators from the University of Bari, Italy presented the preliminary results (as analyzed by the University of Michigan) of our lung cancer trial on October 5th, 2023, to an audience of nearly 5,000 delegates from 103 countries at the 38th Annual EACTS Meeting.
The presentation won:
